Tar Heel Trading Company, LLC (“TTC” or the “Company”) provides drug development organizations with state-of-the-art clinical trial cost benchmarking tools and budgeting applications that are critical to achieving more cost-effective clinical trials. TTC provides its subscribers, consisting of pharmaceutical, biotechnology and medical device companies, as well as clinical research organizations, with access to the most comprehensive set of structured clinical trial cost benchmarking data available in the market. TTC’s data enable subscribers to review and compare their respective clinical trial requirements and budgets against similar, final negotiated clinical trial cost components and budgets for clinical trials conducted by industry peers.
TTC is a highly profitable, privately held business and retained SSG to facilitate the exploration of its strategic alternatives.
After receiving a strong reception from both strategic and financial parties, TTC was acquired by IMS Health (“IMS”), a leading provider of information, services and technology for the healthcare industry around the world. IMS will integrate its evidence-based, anonymized patient and treatment outcomes insights with TTC’s comprehensive cost data drawn from organizations that conduct nearly 80% of all commercial clinical studies. The IMS transaction provides TTC with strategic resources to support its growth initiatives and allows TTC’s owner the opportunity to pursue other business initiatives.